Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma.

MLA

Pinto, A., et al. “Exposure to Obinutuzumab Does Not Affect Outcomes of SARS‐CoV‐2 Infection in Vaccinated Patients with Newly Diagnosed Advanced‐stage Follicular Lymphoma.” British Journal of Haematology, vol. 205, no. 6, Dec. 2024, pp. 2219–27. EBSCOhost, https://doi.org/10.1111/bjh.19661.

APA

Pinto, A., Caltagirone, M., Battista, M., Gazzoli, G. C., Patti, C., Pennese, E., De Lorenzo, S., Pavone, V., Merli, M., Chiarenza, A., Gorgone, A. G., Piazza, F., Puccini, B., Noto, A., Arcaini, L., De Filippi, R., Zinzani, P. L., Ferreri, A. J. M., Ladetto, M., & Ferrari, S. (2024). Exposure to obinutuzumab does not affect outcomes of SARS‐CoV‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma. British Journal of Haematology, 205(6), 2219–2227. https://doi.org/10.1111/bjh.19661

Chicago

Pinto, A., M. Caltagirone, M. Battista, G. C. Gazzoli, C. Patti, E. Pennese, S. De Lorenzo, et al. 2024. “Exposure to Obinutuzumab Does Not Affect Outcomes of SARS‐CoV‐2 Infection in Vaccinated Patients with Newly Diagnosed Advanced‐stage Follicular Lymphoma.” British Journal of Haematology 205 (6): 2219–27. doi:10.1111/bjh.19661.